World-leading infection prevention.

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Us

Prevention is better than cure.

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Our Pipeline

Novel, preventative medicines for the hospital market.

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Our Target Markets

Events

05 July 2023

Microbiome Connect Europe 2023

04 July 2023

BOS Basel 2023

05 June 2023

BIO International Convention
Latest News

25 May 2023

Result of 2023 Annual General Meeting

25 May 2023

Dr Debra Barker Appointed Interim CEO

Share Price

NTCD-M3

Our lead asset, NTCD-M3, targets CDI. The company owns global rights to the world’s most advanced single strain, live bio-therapeutic product ...

…which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI).
Learn More

XF-73 Nasal

XF-73 Nasal is the lead asset from the company’s XF platform ...

…and is a novel compound being developed for the prevention of post-surgical Staphylococcal infections. XF-73 reported very positive clinical data in 2021.
Learn More

XF-73 Dermal

The company is also developing a dermal formulation of XF-73 Dermal for the treatment of bacterial skin infections ...

…and has been supported by the US government’s National Institute for Allergy and Infectious Diseases, (part of the US National Institutes of Health).
Learn More

SPOR-COV™

Destiny Pharma is also collaborating with SporeGen ...

…on a novel SPOR-COV™ innate immune system boosting treatment for the prevention of COVID-19.
Learn More